The identification of new molecular biomarkers that would allow the rapid identification of BC presenting a BRCA1 deficiency could be useful to select patients who could benefit from PARP inhibitors, alkylating agents or platinum-based chemotherapy. Here, BRCA1 is linked to hyperinsulinemic hypoglycemia, familial, 4.